| Andersen, Christen Lykkegaard, Bjørn, Mads Emil, McMullin, Mary Frances, Harrison, Claire, Samuelsson, Jan, Ejerblad, Elisabeth, Zweegman, Sonja, Fernandes, Savio, Bareford, David, Knapper, Steven, Löfvenberg, Eva, Linder, Olle, Andreasson, Bjørn, Ahlstrand, Erik, Jensen, Morten Krogh, Bjerrum, Ole Weis, Vestergaard, Hanne, Larsen, Herdis, Klausen, Tobias Wirenfeldt, Mourits-Andersen, Torben, Skov, Vibe, Thomassen, Mads, Kruse, Torben, Grønbæk, Kirsten and Hasselbalch, Hans Carl 2014. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research 38 (7) , pp. 816-821. 10.1016/j.leukres.2014.04.002 |
Abstract
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P < 0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Medicine |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Publisher: | Elsevier |
| ISSN: | 0145-2126 |
| Date of Acceptance: | 4 April 2014 |
| Last Modified: | 27 Mar 2019 17:03 |
| URI: | http://orca-mwe.cf.ac.uk/id/eprint/79437 |
Citation Data
Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric
Cardiff University Information Services